Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 3 · 60%High 1 · 20%

Adverse events · advanced gastric adenocarcinoma

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 448 participants
Moderate

Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
RR 0.63 [0.56, 0.71]
1 study · 570 participants
Moderate

Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).

1 finding from 1 review

Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).

1 finding from 1 review

Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
RR 1.38 [1.2, 1.59]
1 study · 503 participants
Moderate